ArticleFrontiers in artificial intelligence2025
Lung cancer risk prediction using augmented machine learning pipelines with explainable AI.
Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- CNN-RNN framework for lung cancer classification using CT imaging and GAN-based augmentation.Frontiers in artificial intelligence · 2026Article
- Advancements in artificial intelligence for cancer diagnosis and prognosis prediction: current applications and emerging opportunities.Frontiers in cell and developmental biology · 2026Review
- Artificial Intelligence and Machine Learning in Lung Cancer: Advances in Imaging, Detection, and Prognosis.Cancers · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide, making early and precise diagnosis is critical for improving the patient survival rates. Machine learning has shown promising results in predictive analysis for lung cancer prediction. However, class imbalance in clinical datasets negatively impacts the performance of Machine Learning classifiers, leading to biased predictions and reduced accuracy. In an attempt to address this issue, various data augmentation techniques were applied alongside classification models to enhance predictive performance. This study evaluates data augmentation techniques paired with machine learning classifiers to address class imbalance in a small lung cancer dataset. A comparative analysis was conducted to assess the impact of different augmentation techniques with classification models. Experimental findings demonstrate that K-Means SMOTE, combined with a Multi-Layer Perceptron classifier, achieves the highest accuracy of 93.55% and an AUC-ROC score of 96.76%, surpassing other augmentation-classifier combinations. These results underscore the importance of selecting optimal augmentation methods to improve classification performance. Furthermore, to ensure model interpretability and transparency in medical decision-making, LIME is utilized to provide insights into model predictions. The study highlights the significance of advanced augmentation techniques in addressing data imbalance, ultimately enhancing lung cancer risk prediction through machine learning. The findings contribute to the growing field of AI-driven healthcare by emphasizing the necessity of selecting effective augmentation-classifier pairs to develop more accurate and reliable diagnostic models. Due to the dataset's high cancer prevalence (87.45%) and limited size, this work is a preliminary methodological comparison, not a clinical tool. Findings emphasize the importance of augmentation for imbalanced data and lay the groundwork for future validation with larger, representative datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.